Xinxuekang Regulates Reverse Cholesterol Transport by Improving High-density Lipoprotein Synthesis, Maturation, and Catabolism
- PMID: 28763372
- DOI: 10.1097/FJC.0000000000000500
Xinxuekang Regulates Reverse Cholesterol Transport by Improving High-density Lipoprotein Synthesis, Maturation, and Catabolism
Abstract
Di'ao Xinxuekang (XXK) is an herbal product in China and the Netherlands that has been clinically shown to attenuate atherosclerosis; however, the underlying antiatherosclerotic mechanism remains unclear. Because of its role in cholesterol homeostasis, reverse cholesterol transport (RCT) is a potential target for these beneficial effects. This study investigated the effects of XXK on RCT and related proteins. After treating ApoE-deficient mice with XXK for 8 weeks, we observed an increase in the expression level of ATP-binding cassette transporter A1 and ATP-binding cassette transporter G1, which in turn stimulated cholesterol efflux and reduced aortic atherosclerotic lesion area. XXK also increased high-density lipoprotein (HDL) synthesis by modulating the peroxisome proliferator-activated receptor γ/liver X receptor α/ATP-binding cassette transporter A1 pathway and promoted HDL maturity by increasing serum lecithin-cholesterol acyltransferase. In addition, XXK improved the selective uptake of HDL-cholesteryl ester by increasing the expression of scavenger receptor class B type I. This is the first study to show that XXK confers a regulation of RCT, at least in part, by improving HDL synthesis, maturation, and catabolism.
Similar articles
-
Increased atherosclerosis in P2Y13/apolipoprotein E double-knockout mice: contribution of P2Y13 to reverse cholesterol transport.Cardiovasc Res. 2015 May 1;106(2):314-23. doi: 10.1093/cvr/cvv109. Epub 2015 Mar 13. Cardiovasc Res. 2015. PMID: 25770145
-
Reverse cholesterol transport and cholesterol efflux in atherosclerosis.QJM. 2005 Dec;98(12):845-56. doi: 10.1093/qjmed/hci136. Epub 2005 Oct 28. QJM. 2005. PMID: 16258026 Review.
-
EP 80317, a CD36 selective ligand, promotes reverse cholesterol transport in apolipoprotein E-deficient mice.Atherosclerosis. 2013 Aug;229(2):408-14. doi: 10.1016/j.atherosclerosis.2013.05.031. Epub 2013 Jun 14. Atherosclerosis. 2013. PMID: 23880196
-
Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity.Rejuvenation Res. 2009 Apr;12(2):117-26. doi: 10.1089/rej.2009.0840. Rejuvenation Res. 2009. PMID: 19405812 Review.
-
Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance.Circ Res. 2006 Sep 15;99(6):598-606. doi: 10.1161/01.RES.0000242559.42077.22. Epub 2006 Aug 24. Circ Res. 2006. PMID: 16931800 Free PMC article.
Cited by
-
Di'ao Xinxuekang Capsule Improves the Anti-Atherosclerotic Effect of Atorvastatin by Downregulating the SREBP2/PCSK9 Signalling Pathway.Front Pharmacol. 2022 Apr 28;13:857092. doi: 10.3389/fphar.2022.857092. eCollection 2022. Front Pharmacol. 2022. PMID: 35571088 Free PMC article.
-
Atheroprotective Effects and Mechanisms of Postmarketing Chinese Patent Formulas in Atherosclerosis Models: A Systematic Review.Evid Based Complement Alternat Med. 2021 Nov 27;2021:4010607. doi: 10.1155/2021/4010607. eCollection 2021. Evid Based Complement Alternat Med. 2021. PMID: 34873408 Free PMC article. Review.
-
Di'ao Xinxuekang Capsule, a Chinese Medicinal Product, Decreases Serum Lipids Levels in High-Fat Diet-Fed ApoE-/- Mice by Downregulating PCSK9.Front Pharmacol. 2018 Nov 1;9:1170. doi: 10.3389/fphar.2018.01170. eCollection 2018. Front Pharmacol. 2018. PMID: 30443213 Free PMC article.
-
The Signaling Pathways Involved in the Antiatherosclerotic Effects Produced by Chinese Herbal Medicines.Biomed Res Int. 2018 Jun 13;2018:5392375. doi: 10.1155/2018/5392375. eCollection 2018. Biomed Res Int. 2018. PMID: 30009170 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
